ATXS Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Astria Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.06 |
| 52 Week High | US$16.90 |
| 52 Week Low | US$4.26 |
| Beta | 0.74 |
| 11 Month Change | 3.79% |
| 3 Month Change | 33.85% |
| 1 Year Change | 34.15% |
| 33 Year Change | 28.16% |
| 5 Year Change | -68.25% |
| Change since IPO | -98.45% |
Recent News & Updates
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11
Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
Jun 24Recent updates
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
Jun 24Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
Feb 04We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Dec 10We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Jul 27We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
Apr 03Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Nov 30We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Aug 01Dr. Chris Morabito is the new medical chief of Astria Therapeutics
Jul 15Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
Jun 30Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital
Jun 15Catabasis Pharma shares surge after Quellis Biosciences deal
Jan 29Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?
Dec 10
Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 29Shareholder Returns
| ATXS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | -0.4% | -0.8% |
| 1Y | 34.1% | 13.7% | 21.5% |
Return vs Industry: ATXS exceeded the US Biotechs industry which returned 14% over the past year.
Return vs Market: ATXS exceeded the US Market which returned 22.9% over the past year.
Price Volatility
| ATXS volatility | |
|---|---|
| ATXS Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATXS's share price has been volatile over the past 3 months.
Volatility Over Time: ATXS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 59 | Jill Milne | www.astriatx.com |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.
Astria Therapeutics, Inc. Fundamentals Summary
| ATXS fundamental statistics | |
|---|---|
| Market cap | US$685.00m |
| Earnings (TTM) | -US$93.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.3x
P/E RatioIs ATXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATXS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$93.24m |
| Earnings | -US$93.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATXS perform over the long term?
See historical performance and comparison